18 research outputs found
ARDD 2020: from aging mechanisms to interventions
Aging is emerging as a druggable target with growing interest from academia, industry and investors. New technologies such as artificial intelligence and advanced screening techniques, as well as a strong influence from the industry sector may lead to novel discoveries to treat age-related diseases. The present review summarizes presentations from the 7th Annual Aging Research and Drug Discovery (ARDD) meeting, held online on the 1st to 4th of September 2020. The meeting covered topics related to new methodologies to study aging, knowledge about basic mechanisms of longevity, latest interventional strategies to target the aging process as well as discussions about the impact of aging research on society and economy. More than 2000 participants and 65 speakers joined the meeting and we already look forward to an even larger meeting next year. Please mark your calendars for the 8th ARDD meeting that is scheduled for the 31st of August to 3rd of September, 2021, at Columbia University, USA
The Antioxidant Cofactor Alpha-Lipoic Acid May Control Endogenous Formaldehyde Metabolism in Mammals
Thiamine preserves mitochondrial function in a rat model of traumatic brain injury, preventing inactivation of the 2-oxoglutarate dehydrogenase complex
Background and purpose: Based on the fact that traumatic brain injury is associated with mitochondrial dysfunction we aimed at localization of mitochondrial defect and attempted to correct it by thiamine. Experimental approach: Interventional controlled experimental animal study was used. Adult male Sprague-Dawley rats were subjected to lateral fluid percussion traumatic brain injury. Thiamine was administered 1 h prior to trauma; cortex was extracted for analysis 4 h and 3 d after trauma. Key results: Increased expression of inducible nitric oxide synthase (iNOS) and tumor necrosis factor receptor 1 (TNF-R1) by 4 h was accompanied by a decrease in mitochondrial respiration with glutamate but neither with pyruvate nor succinate. Assays of TCA cycle flux-limiting 2-oxoglutarate dehydrogenase complex (OGDHC) and functionally linked enzymes (glutamate dehydrogenase, glutamine synthetase, pyruvate dehydrogenase, malate dehydrogenase and malic enzyme) indicated that only OGDHC activity was decreased. Application of the OGDHC coenzyme precursor thiamine rescued the activity of OGDHC and restored mitochondrial respiration. These effects were not mediated by changes in the expression of the OGDHC sub-units (E1k and E3), suggesting post-translational mechanism of thiamine effects. By the third day after TBI, thiamine treatment also decreased expression of TNF-R1. Specific markers of unfolded protein response did not change in response to thiamine. Conclusion and implications: Our data point to OGDHC as a major site of damage in mitochondria upon traumatic brain injury, which is associated with neuroinflammation and can be corrected by thiamine. Further studies are required to evaluate the pathological impact of these findings in clinical settings
The Antioxidant Cofactor Alpha-Lipoic Acid May Control Endogenous Formaldehyde Metabolism in Mammals
The healthy human body contains small amounts of metabolic formaldehyde (FA) that mainly results from methanol oxidation by pectin methylesterase, which is active in a vegetable diet and in the gastrointestinal microbiome. With age, the ability to maintain a low level of FA decreases, which increases the risk of Alzheimer's disease and dementia. It has been shown that 1,2-dithiolane-3-pentanoic acid or alpha lipoic acid (ALA), a naturally occurring dithiol and antioxidant cofactor of mitochondrial α-ketoacid dehydrogenases, increases glutathione (GSH) content and FA metabolism by mitochondrial aldehyde dehydrogenase 2 (ALDH2) thus manifests a therapeutic potential beyond its antioxidant property. We suggested that ALA can contribute to a decrease in the FA content of mammals by acting on ALDH2 expression. To test this assumption, we administered ALA in mice in order to examine the effect on FA metabolism and collected blood samples for the measurement of FA. Our data revealed that ALA efficiently eliminated FA in mice. Without affecting the specific activity of FA-metabolizing enzymes (ADH1, ALDH2, and ADH5), ALA increased the GSH content in the brain and up-regulated the expression of the FA-metabolizing ALDH2 gene in the brain, particularly in the hippocampus, but did not impact its expression in the liver in vivo or in rat liver isolated from the rest of the body. After ALA administration in mice and in accordance with the increased content of brain ALDH2 mRNA, we detected increased ALDH2 activity in brain homogenates. We hypothesized that the beneficial effects of ALA on patients with Alzheimer's disease may be associated with accelerated ALDH2-mediated FA detoxification and clearance
Aging and drug discovery
Multiple interventions in the aging process have been discovered to extend the healthspan of model organisms.
Both industry and academia are therefore exploring possible transformative molecules that target aging and
age‐associated diseases. In this overview, we summarize the presented talks and discussion points of the 5th
Annual Aging and Drug Discovery Forum 2018 in Basel, Switzerland. Here academia and industry came
together, to discuss the latest progress and issues in aging research. The meeting covered talks about the
mechanistic cause of aging, how longevity signatures may be highly conserved, emerging biomarkers of aging,
possible interventions in the aging process and the use of artificial intelligence for aging research and drug
discovery. Importantly, a consensus is emerging both in industry and academia, that molecules able to
intervene in the aging process may contain the potential to transform both societies and healthcareDB is supported by the German Research Foundation
(Forschungsstipendium; BA 6276/1-1). CYE is
supported by Swiss National Science Foundation
[163898]. VNG is supported by grants from National
Institutes of Health, and by the Russian Federation grant
14.W03.31.0012. DWL presented the results of research
supported in part by research grants and funds from the
National Institutes of Health, the Wisconsin Partnership
Program, the Progeria Research Foundation, the
American Federation for Aging Research, and the University of Wisconsin-Madison School of Medicine
and Public Health and Department of Medicine, as well
as the facilities and resources of the William S.
Middleton Memorial Veterans Hospital. The content is
solely the responsibility of the authors and does not
necessarily represent the official views of the NIH. This
work does not represent the views of the Department of
Veterans Affairs or the United States Government. MSL
is supported by an LUMC research fellowship and a
VIDI grant from the Netherlands scientific organization
(NWO- ALW-016.161.320). A.M.-M. is supported by
grants from the Instituto de Salud Carlos III co-funded
by Instituto de Salud Carlos III and FEdeR
(CP14/00105 and PI15/00134). SM was supported by
the FWO-OP/Odysseus program
(42/FA010100/32/6484). SJO's current work is funded
by The Glenn Award from the Glenn Foundation for
Medical Research. MR is supported by the Swiss
National Science Foundation and the European Union
Horizon 2020 program. MSK is supported by grants
from the Danish Cancer Society (#R167-A11015_001),
the Independent Research Fund Denmark (#7016-
00230B) and the Novo Nordisk Foundation
(NNF17OC0027812).Peer reviewe